{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:00:22Z","timestamp":1792425622524,"version":"4.5.0"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Inflammatory dermatological conditions, including psoriasis, lichen planus, eczema, and alopecia areata, are frequently accompanied by nail findings and can have a significant impact on quality of life. Biologic and small-molecule medications have been approved over the past several decades in treating patients with these inflammatory nail disorders. They may be used in conjunction with longstanding mainstays of treatment (topical and intralesional corticosteroids, topical vitamin D3 analogs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Our objectives were to review biologic and small-molecule treatment efficacies for nail psoriasis and alopecia areata-associated nail dystrophy, including Janus kinase inhibitors, apremilast, tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, and IL-23 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A comprehensive PubMed literature review of clinical research studies, narrative reviews, systematic reviews, and meta-analyses was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Many biologics and small molecules are effective in treating nail psoriasis and alopecia areata, with each requiring precautions for adverse events. Clinical trials for use of biologics and small molecules for nail lichen planus and atopic dermatitis have not been published to date.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_445_24","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T14:00:07Z","timestamp":1735221607000},"page":"50-58","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review"],"prefix":"10.4103","volume":"16","author":[{"given":"Carrie A.","family":"Forman","sequence":"first","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"R2-20241226","doi-asserted-by":"crossref","first-page":"2050313 231213149","DOI":"10.1177\/2050313X231213149","article-title":"A case of rapid fingernail growth associated with nail psoriasis:A case report","volume":"11","author":"Conway","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"R3-20241226","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/keh198","article-title":"Extended report:Nail disease in psoriatic arthritis\u2014clinically important, potentially treatable and often overlooked","volume":"43","author":"Williamson","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R4-20241226","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1038\/s41598-019-43899-9","article-title":"Th1, Th17, and treg responses are differently modulated by TNF-? inhibitors and methotrexate in psoriasis patients","volume":"9","author":"Furiati","year":"2019","journal-title":"Sci Rep"},{"key":"R5-20241226","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","article-title":"Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis:A dermatologist and nail expert group consensus","volume":"81","author":"Rigopoulos","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R7-20241226","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","article-title":"Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Beh\u00e7et's syndrome","volume":"24","author":"Mease","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"R8-20241226","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2217\/imt-2022-0109","article-title":"Deucravacitinib in moderate-to-severe psoriasis","volume":"14","author":"Vu","year":"2022","journal-title":"Immunotherapy"},{"key":"R10-20241226","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40259-013-0040-7","article-title":"The arrival of JAK inhibitors:Advancing the treatment of immune and hematologic disorders","volume":"27","author":"Furumoto","year":"2013","journal-title":"BioDrugs"},{"key":"R13-20241226","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"R14-20241226","first-page":"1046","article-title":"Characteristics of adverse event reporting of Xeljanz\/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration","volume":"28","author":"Qian","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"R15-20241226","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0253-7613.178821","article-title":"Meyler's side effects of drugs:The international encyclopedia of adverse drug reactions and interactions","volume":"48","author":"Desai","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"R18-20241226","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/tcrm.2007.3.1.99","article-title":"Etanercept in the treatment of rheumatoid arthritis","volume":"3","author":"Haraoui","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"R20-20241226","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases:A systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R21-20241226","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.1.5.9286","article-title":"Golimumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"MAbs"},{"key":"R23-20241226","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/annrheumdis-2013-204195","article-title":"Golimumab 3-year safety update:An analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis","volume":"74","author":"Kay","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R24-20241226","first-page":"841","article-title":"Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh","year":"2000","journal-title":"The Journal of Rheumatology"},{"key":"R26-20241226","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"R28-20241226","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2147\/DDDT.S113683","article-title":"Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis:Design, development, and potential place in therapy","volume":"11","author":"Roman","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"R30-20241226","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res"},{"key":"R34-20241226","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40257-018-0406-1","article-title":"Guselkumab:A review in moderate to severe plaque psoriasis","volume":"19","author":"Al-Salama","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R36-20241226","doi-asserted-by":"crossref","first-page":"110331","DOI":"10.1016\/j.intimp.2023.110331","article-title":"Current and emerging prospects in the psoriatic treatment","volume":"120","author":"Rutuja","year":"2023","journal-title":"International Immunopharmacology"},{"key":"R38-20241226","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis:24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R39-20241226","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5114\/reum.2019.87620","article-title":"Tildrakizumab in the treatment of psoriasis-Literature review","volume":"57","author":"Banaszczyk","year":"2019","journal-title":"Reumatologia"},{"key":"R40-20241226","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1756283X10374216","article-title":"Review of the safety and efficacy of ustekinumab","volume":"3","author":"Scherl","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"R41-20241226","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab:A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"R43-20241226","doi-asserted-by":"crossref","first-page":"620562","DOI":"10.3389\/fmed.2021.620562","article-title":"Efficacy of systemic treatments of nail psoriasis:A systemic literature review and meta-analysis","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R44-20241226","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1080\/09546634.2021.1892024","article-title":"Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis","volume":"33","author":"Reich","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"R45-20241226","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s13555-020-00383-x","article-title":"Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis:52-week results from a phase 3, head-to-head study (IXORA-S)","volume":"10","author":"Wasel","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R46-20241226","doi-asserted-by":"crossref","first-page":"e2022104","DOI":"10.5826\/dpc.1202a104","article-title":"Efficacy and safety of ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis:52-week results from the randomized SPIRIT-H2H trial","volume":"12","author":"Reich","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"R47-20241226","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R48-20241226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis:Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2","volume":"74","author":"Rich","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R49-20241226","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/jdv.17387","article-title":"Development and validation of the physician's global assessment of fingernail psoriasis","volume":"35","author":"Hudgens","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R50-20241226","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis:Efficacy and safety results from the 52-week trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R51-20241226","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/TCRM.S388324","article-title":"Clinical utility of deucravacitinib for the management of moderate to severe plaque psoriasis","volume":"19","author":"Jin","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"R52-20241226","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis:Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R53-20241226","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40744-023-00589-3","article-title":"Treatment with upadacitinib in active psoriatic arthritis:Efficacy and safety data of the first 192 patients from the UPJOINT study, a multicentre, observational study in clinical practice","volume":"10","author":"Werner","year":"2023","journal-title":"Rheumatol Ther"},{"key":"R54-20241226","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index:Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J Rheumatol"},{"key":"R55-20241226","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/jdv.15793","article-title":"Adalimumab for nail psoriasis:Efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial","volume":"33","author":"Elewski","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R56-20241226","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"R57-20241226","doi-asserted-by":"crossref","first-page":"adv00214","DOI":"10.2340\/00015555-3545","article-title":"Efficacy of adalimumab for nail psoriasis during 24 months of continuous therapy","volume":"100","author":"Kokolakis","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R58-20241226","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis:24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R59-20241226","doi-asserted-by":"crossref","first-page":"e000582","DOI":"10.1136\/rmdopen-2017-000582","article-title":"4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis","volume":"4","author":"van der Heijde","year":"2018","journal-title":"RMD Open"},{"key":"R60-20241226","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"Br J Dermatol"},{"key":"R61-20241226","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr2.11180","article-title":"Evaluation of improvement in skin and nail psoriasis in bio-na\u00efve patients with active psoriatic arthritis treated with golimumab:Results through week 52 of the GO-VIBRANT study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R62-20241226","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis:A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"R63-20241226","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-? inhibitors:A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"R64-20241226","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2020.1749546","article-title":"Efficacy of brodalumab in the treatment of scalp and nail psoriasis:Results from three phase 3 trials","volume":"33","author":"Elewski","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R65-20241226","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s13555-022-00704-2","article-title":"Simultaneous nail and skin clearance in ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis","volume":"12","author":"Elewski","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R66-20241226","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis:2.5-year results from the randomized placebo-controlled TRANSFIGURE study","volume":"184","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"R67-20241226","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions:A secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R68-20241226","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13075-023-03138-z","article-title":"Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis:A post hoc analysis of the VOYAGE 2 randomized trial","volume":"25","author":"Tillett","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"R69-20241226","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/jcm13020495","article-title":"Effectiveness, tolerability, and drug survival of risankizumab in a real-world setting:A three-year retrospective multicenter study-IL PSO (ITALIAN LANDSCAPE PSORIASIS","volume":"13","author":"Gargiulo","year":"2024","journal-title":"J Clin Med"},{"key":"R70-20241226","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jdv.18572","article-title":"Real-world effectiveness and safety of tildrakizumab in long-term treatment of Plaque Psoriasis:Results from the non-interventional, prospective, multicentre study TILOT","volume":"37","author":"Tsianakas","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R71-20241226","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"PHOENIX1 investigators. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis:Results from PHOENIX1","volume":"170","author":"Rich","year":"2014","journal-title":"Br J Dermatol"},{"key":"R72-20241226","first-page":"114","article-title":"Nail changes in alopecia areata:Incidence and pattern","volume":"69","author":"Gandhi","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R73-20241226","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jocd.16049","article-title":"Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran","volume":"23","author":"Asilian","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"R74-20241226","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/09546634.2018.1466024","article-title":"Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib","volume":"29","author":"Lee","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"R75-20241226","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.annder.2022.01.010","article-title":"Nail lichen planus:A review of clinical presentation, diagnosis and therapy","volume":"149","author":"Grover","year":"2022","journal-title":"Ann Dermatol Venereol"},{"key":"R76-20241226","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jdcr.2021.09.015","article-title":"Clinical features and treatment outcomes of nail lichen planus:A retrospective study","volume":"17","author":"Wechsuruk","year":"2021","journal-title":"JAAD Case Rep"},{"key":"R77-20241226","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdcr.2020.10.024","article-title":"Onychodystrophy associated with dupilumab therapy for atopic dermatitis","volume":"7","author":"Zubek","year":"2020","journal-title":"JAAD Case Rep"},{"key":"R78-20241226","doi-asserted-by":"crossref","first-page":"e15010","DOI":"10.1111\/exd.15010","article-title":"Prospective evaluation of cardiovascular risk and mortality in patients with psoriasis:An American population-based study","volume":"33","author":"Kan","year":"2024","journal-title":"Exp Dermatol"},{"key":"R79-20241226","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure:Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"R80-20241226","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/ehf2.13855","article-title":"Comparison of the risk of heart failure in psoriasis patients using anti-TNF \u03b1 inhibitors and ustekinumab","volume":"9","author":"Han","year":"2022","journal-title":"ESC Heart Fail"},{"key":"R81-20241226","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3390\/jcm12031162","article-title":"Biologics for reducing cardiovascular risk in psoriasis patients","volume":"12","author":"Terui","year":"2023","journal-title":"J Clin Med"},{"key":"R82-20241226","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of psoriasis with inflammatory bowel disease:A systematic review and meta-analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R83-20241226","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"Placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R84-20241226","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations:A review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"R85-20241226","first-page":"81","article-title":"A narrative review of psoriasis and multiple sclerosis:Links and risks","volume":"9","author":"Silfvast-Kaiser","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"R86-20241226","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cyto.2008.11.002","article-title":"Inflammatory demyelinating events following treatment with anti-tumor necrosis factor","volume":"45","author":"Fromont","year":"2009","journal-title":"Cytokine"},{"key":"R87-20241226","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS:Results from a randomized, proof-of-concept study","volume":"263","author":"Havrdov\u00e1","year":"2016","journal-title":"J Neurol"},{"key":"R88-20241226","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1513\/AnnalsATS.201701-055ED","article-title":"Minimizing tuberculosis risk in patients receiving anti-TNF therapy","volume":"14","author":"Esmail","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"R89-20241226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","article-title":"National psoriasis foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents","volume":"59","author":"Doherty","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R90-20241226","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0026-2016","article-title":"Biologic agents and tuberculosis","volume":"4","author":"Dobler","year":"2016","journal-title":"Microbiol Spectr"},{"key":"R91-20241226","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ijd.15217","article-title":"QuantiFERON TB-gold conversion rate among psoriasis patients under biologics:A 9-year retrospective study","volume":"60","author":"Megna","year":"2021","journal-title":"Int J Dermatol"},{"key":"R92-20241226","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijwd.2016.12.003","article-title":"Update on biologic safety for patients with psoriasis during pregnancy","volume":"3","author":"Porter","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"R93-20241226","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5114\/ada.2020.102089","article-title":"The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation:A review of current clinical guidelines","volume":"37","author":"Owczarek","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"R94-20241226","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2147\/CCID.S433367","article-title":"JAK inhibitors in psoriatic disease","volume":"16","author":"Megna","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R95-20241226","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral interleukin-23-receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N Engl J Med"},{"key":"R96-20241226","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40265-023-01988-0","article-title":"Spesolimab for the treatment of generalized pustular psoriasis","volume":"84","author":"Bernardo","year":"2024","journal-title":"Drugs"},{"key":"R97-20241226","doi-asserted-by":"crossref","first-page":"e13682","DOI":"10.1111\/cts.13682","article-title":"Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"R98-20241226","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jaad.2023.05.049","article-title":"Janus kinase inhibitors for alopecia areata","volume":"89","author":"King","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R99-20241226","doi-asserted-by":"crossref","first-page":"1135145","DOI":"10.3389\/fphar.2023.1135145","article-title":"Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents:A review","volume":"14","author":"Jain","year":"2023","journal-title":"Front Pharmacol"},{"key":"R100-20241226","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R?) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"R101-20241226","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3389\/fimmu.2019.01808","article-title":"Therapeutic targeting of Th17\/Tc17 cells leads to clinical improvement of lichen planus","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"R102-20241226","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/pharmaceutics15020568","article-title":"Targeting interleukin 13 for the treatment of atopic dermatitis","volume":"15","author":"Lytvyn","year":"2023","journal-title":"Pharmaceutics"},{"key":"R103-20241226","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/pharmaceutics15020577","article-title":"Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis","volume":"15","author":"Orfali","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_445_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:24Z","timestamp":1786649964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_445_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_445_24","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"2024-05-11 2024-09-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}